Clinical Trial Update: Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) [Phase 2]

View source ↗

Summary

A Phase 2 MATCH-subprotocol Q trial evaluating ado-trastuzumab emtansine (T-DM1) for cancers with HER2 genetic changes; results were posted in 2021, and the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Lymphoma
• Multiple Myeloma
• Solid Malignant Neoplasm

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-02-05